Intramyocardial Angiogenic Cell Precursor Injection for Cardiomyopathy

Arom, Kitipan V.; Ruengsakulrach, Permyos; Jotisakulratana, Vibul

doi:10.1177/021849230801600213

Cited by 25 publications

(14 citation statements)

References 18 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The coronary disease and cardiac insufficiency are responsible for the greatest index of morbidity in occidental society, with a high rate of mortality [36]. There are many diseases which can affect the good functioning of cardiac muscle: coronary diseases [37], myocardial infarction [38], Chagas disease [39], and other myocardiopathies [40]. Several cell lines like embryonic stem cells, nuclear cells of marrow bone, myoblasts, endothelial and mesenchymal progenitors and cardiac stem cells were used with varied effectiveness and safety in pre-clinical and clinical rehearsals, in the treatment of acute myocardial infarction and chronic heart failure [41], showing an improvement of the cardiac function after the cellular therapy [42].…”

Section: Cardiologymentioning

confidence: 99%

Mesenchymal Stem Cells X Lateral Amyotrophic Sclerosis - Las

Basso¹

2017

Stem Cells Regen Med

View full text Add to dashboard Cite

The mesenchymal stem cells can be expanded ex vivo and are capable to differentiate in several lineages, represent a rare subpopulation of the bone marrow cells (< 0, 01% of the mononuclear cells of bone marrow) with mitotic expansion capacity in vitro. As a result of the facility in dividing and proliferate, we concluded that the mesenchymal stem cells would be responsible for the maintenance and renovation of adult mesenchymal tissues. This cell type presents as one of its virtues a considerable immunomodulatory activity, avoiding any adverse effects. We believe that, overcoming some challenges in its isolation, preparation and infusion mode, due to these characteristics, the MSC represent promising tools for cell therapy, mostly the ones associated to bone marrow transplantation. The amyotrophic lateral sclerosis (ALS) still is a disease of unknown cause nowadays, despite knowledge of many of its aspects have advanced since Charcot's epoch. Many theories were proposed for its pathogen; however, none of them has showed unifying until now. These would have to explain the different degrees of incidence in several geographic areas, the distinct forms of clinic presentation, time of evolution, as well as the vulnerability and resistance of determined neuronal populations. It is possible that we are in front of many anatomical-clinical entities of multiple etiologies, which are presented in a similar form. This work showed that MSC cultures can be obtained starting from samples of bone marrow of healthy donors through standard of processing protocols, cultivation and characterization in vitro, and even of autologous donors.

show abstract

Section: Cardiologymentioning

confidence: 99%

Mesenchymal Stem Cells X Lateral Amyotrophic Sclerosis - Las

Basso¹

2017

Stem Cells Regen Med

View full text Add to dashboard Cite

show abstract

“…An array test showing that the cells secreted IL-8, VEGF and angiogenin was used to assess the product potency and later to narrow the range of tested cytokines to IL-8, which was subsequently used as a release test for the CTP [23]. Validation of the surrogate markerebased tests was achieved when the CTP was tested and shown to be effective in an in vivo rat model of ischemic cardiomyopathy [24] and in human patients with ischemic and non-ischemic cardiomyopathy [25,26] (Figure 3).…”

Section: The Ctp Intended Effect: Moa and Surrogate Markersmentioning

confidence: 99%

Critical elements in the development of cell therapy potency assays for ischemic conditions

et al. 2015

View full text Add to dashboard Cite

“…44 Other diseases also cause myocardial dysfunction, such as Chagas disease and other cardiomyopathies. 45 Advances in the treatment of cardiovascular diseases are due, in part, from the development of coronary revascularization techniques, and pacemaker and defibrillator implantation. With the exception of heart transplantation, these treatment options are limited by their incapacity to substitute lost cardiomyocytes and myocardial scars, and this is aggravated by the incapacity of the heart to replace its cell mass through self-renewal.…”

Section: Regenerative Medicinementioning

confidence: 99%

Células-tronco de tecido adiposo e a importância da padronização de um modelo animal para experimentação pré-clínica

Zuttion¹,

Wenceslau²,

Lemos³

et al. 2013

Rev. Bras. Cardiol. Invasiva

View full text Add to dashboard Cite

Stem cells are undifferentiated cells and can self-renew and differentiate into various cell types, besides having immunomodulating properties and paracrine effects in response to tissue injury, and may therefore treat injuries and diseases or even replace damaged or lost cells. Adipose tissue is an attractive source of adult stem cells, since the human body has a large reserve that is obtained in large amounts by minimally invasive methods. Interest in these cells has been increasing steadily due to their properties and possible applications in regenerative medicine and cell therapy. A large part of these investigations are focused on cardiovascular diseases, which are a leading cause of morbidity and mortality worldwide. Although in recent years treatments have advanced in cardiology, the development of new therapies to recover the damaged tissue still remains one of the main goals of cardiac research. However, to achieve effective results, in vivo and in vitro animal models for preclinical studies and consequently for application in humans must be standardized. The development of preclinical models in large animals requires the use of well-characterized animal cell lines, similar to human cells, and the use of the porcine model represents a great advantage for preclinical translational research. DESCRIPTORS: Original Article RESUMO Células-Tronco de Tecido Adiposo e a Importância da Padronização de um Modelo Animal para Experimentação Pré-ClínicaAs células-tronco são células indiferenciadas, capazes de se autorrenovar e de se diferenciarem em diversos tipos celulares, além de apresentarem propriedades imunomoduladoras e efeitos parácrinos mediante injúria tecidual, podendo, dessa forma, tratar lesões e doenças ou ainda substituir células danificadas ou perdidas. Dentre as fontes de células-tronco adultas, o tecido adiposo é uma fonte atrativa, pois o organismo humano possui grande reserva desse tecido, que, por sua vez, é obtido em grandes quantidades por meio de métodos pouco invasivos. O interesse nessas células vem aumentando constantemente devido a suas propriedades e possíveis aplicações na medicina regenerativa e terapia celular. Grande parte dessas pesquisas está voltada para doenças cardiovasculares, que são a principal causa de morbidade e mortalidade em todo o mundo. Embora nos últimos anos, os tratamentos em cardiologia tenham avançado, o desenvolvimento de novas terapias que recuperem o tecido danificado ainda permanece como um dos objetivos principais das pesquisas cardíacas. Porém, para obter resultados eficazes, é necessária a padronização de modelos animais in vivo e in vitro para estudos pré-clínicos e, consequentemente, a aplicação em humanos. O desenvolvimento de modelos pré-clínicos em animais de grande porte exige o uso bem caracterizado de linhagens de células animais semelhantes aos seus equivalentes humanos. O modelo suíno representa uma grande vantagem para a investigação translacional pré-clínica.

show abstract

Intramyocardial Angiogenic Cell Precursor Injection for Cardiomyopathy

Cited by 25 publications

References 18 publications

Mesenchymal Stem Cells X Lateral Amyotrophic Sclerosis - Las

Mesenchymal Stem Cells X Lateral Amyotrophic Sclerosis - Las

Critical elements in the development of cell therapy potency assays for ischemic conditions

Células-tronco de tecido adiposo e a importância da padronização de um modelo animal para experimentação pré-clínica

Contact Info

Product

Resources

About